[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"advanced-milignant-gliomas\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:advanced-milignant-gliomas":42},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":4},"100247241",false,"NCT02496988","Effect of Cytokine-induced Killer Cells for Advanced Malignant Gliomas","A Study of CIK in Combination With Temozolomide With and Without Radiation in Adults With Advanced Malignant Gliomas","Inclusion Criteria:\n\n* Subjects with documented histologically confirmed primary grade 4 advanced malignant glioma.\n* No more than 3 prior relapses or prior systemic treatments.\n* Recurrent disease documented by MRI after prior therapy.\n* Must have at least one site of bidimensionally measurable disease:\n\narchived tissue from the initial diagnosis of advanced malignant glioma or upon transformation to advanced malignant glioma are available for central review within approximately 4 weeks after enrollment.\n\n* Completed at least one full cycle of temozolomide of 200 mg\u002Fm2\u002Fday administered on Days 1-5 of a 28-day cycle, without unacceptable toxicity or progression.\n* Karnofsky performance status of 60 or more. Adequate organ and bone marrow function as defined by hematological and serum chemistry limits.\n* At least 18 years old.\n* Both men and women must practice adequate contraception.\n* Informed consent.\n\nExclusion Criteria:\n\n* Progressed while on temozolomide.\n* Evidence of acute intracranial or intratumoral hemorrhage \\> Grade 1.\n* Not recovered from the toxic effects of prior therapy.\n* Pregnant or breast feeding.\n* History of diabetes mellitus.\n* Uncontrolled intercurrent illness.\n* Congestive heart failure, unstable angina, or a myocardial infarction within 3 months of entering the study.\n* HIV positive.\n* Diagnosis of another malignancy may exclude subject from study.","ALL","18 Years","80 Years",{"count":19,"type":20},120,"ESTIMATED","INTERVENTIONAL",[23],"PHASE4","The purpose of this study is to determine whether combining of Temozolomide and cytokine-induced killer cells (CIK) transfusion can prolong survival of patients with Advanced Malignant Gliomas. The effectiveness and safety of CIK cells for the treatment of Malignant Glioma is also evaluated.",[26,27],"Cytokine-Induced Killer Cells","Advanced Milignant Gliomas",[26,29,30],"Milignant Gliomas","Temozolomide","NOT_YET_RECRUITING","2015-07-13",{"date":34,"type":20},"2015-07-14",{"date":36,"type":4},"2015-07",{"date":38,"type":20},"2030-07",{"name":40,"class":41},"The First People's Hospital of Changzhou","OTHER",""]